Menu

Recent Interviews

Lewis Black, CEO, Almonty Industries

Lewis Black
CEO | Almonty Industries
100 King Street West, M5X 1C7 Toronto (CAN)

info@almonty.com

+1 (647) 438-9766

Interview with mine operator Almonty Industries: "Tungsten makes e-cars better"


Nick Luksha, President, Prospect Ridge Resources

Nick Luksha
President | Prospect Ridge Resources
1288 West Cordova Street Suite 2807, V6C 3R3 Vancouver (CAN)

info@prospectridgeresources.com

Interview Prospect Ridge Resources: These fillets taste good to the market


Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


08. November 2021 | 12:08 CET

BioNTech, Moderna, Cardiol Therapeutics, Valneva: COVID-19, the vaccination chaos is perfect!

  • Biotechnology
Photo credits: pixabay.com

Now the chaos is perfect. According to studies, the preparation from BioNTech/Pfizer is one of the most effective vaccines against the coronavirus. Hundreds of millions of doses have already been administered worldwide. However, the number of COVID infections is currently through the roof. Even those who have been vaccinated twice are likely still not sufficiently protected against infection. There are also unsettling rumors from BioNTech about irregularities in the conduct of studies during the vaccine's approval. Whether it concerns thereby only "rumors" or "provable facts", the capital investors do not care for the time being. They pressed the sell button and thus sent the entire peer group Adhoc into the basement. We take a closer look at the chaos.

time to read: 4 minutes by André Will-Laudien
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , MODERNA INC. DL-_0001 | US60770K1079 , CARDIOL THERAPEUTICS | CA14161Y2006 , VALNEVA SE EO -_15 | FR0004056851


 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


BioNTech and Moderna - Share price collapse due to wild rumors and whistleblowers

The two top dogs in the vaccine business saw a sell-off on Friday. The reason is that serious allegations have been made against a subcontractor of Pfizer commissioned with clinical studies on the Corona vaccine. As the renowned journal "British Medical Journal" (BMJ) reported regarding an ex-employee of Ventavia, the Company from the US state of Texas is alleged to have falsified data in studies on the vaccine from BioNTech/Pfizer and to have slopped in the tracking of side effects.

The BMJ report is based largely on testimony from former Ventavia employee Brook Jackson. She was involved in the Company's clinical trials of the Corona vaccine for two weeks before she was fired. Among other things, Jackson, a whistleblower, accuses Ventavia of failing to implement the so-called double-blind procedure involving placebos. The aim of this is to enable the most objective possible evaluation of the study results. Allegedly, the FDA has already been informed about this deficiency but did not want to comment on the matter when asked.

It also fits into the opaque situation that Moderna announced weak figures last week. The partner company of BionNTech Pfizer is said to have developed its own drug for oral administration against COVID-19. On Friday, there were also rumors about the alleged arrest of Pfizer CEO Albert Bourla in Canada, which quickly turned out to be a false spread.

But this could not help the prices of BioNTech and Moderna at the end of last week. Both values said goodbye with a decline of more than 20% into the weekend. USD 35 billion shareholder capital dissolved into thin air within 24 hours. If the last analyst estimates are still valid, BioNTech is now trading at a P/E of only 6.5 and Moderna at 11.5. The shares have rarely been this cheap. Nevertheless, we wait and see how the news develops.

Cardiol Therapeutics - Capital increase for clinical studies

It happens again and again that rapidly growing companies resort to capital increases with certain price dynamics. At this moment, the medium-term investor realizes that a stock market listing is equivalent to the original idea of financing growth and does not have to be centrally in line with investor interests. So if good prospects often drive up share prices, even irrationally, it is only fitting that a company's founders and board members should seize the opportunity to raise additional equity capital for the Company.

In Germany, existing shareholders are protected from dilution by the so-called subscription right if they subscribe per the allotted right. In Anglo-Saxon countries, the possibility also exists for larger capital measures with the waiver of the rights of the existing shareholders. In the case of Cardiol Therapeutics Inc., this approach has happened twice now in 2021. Looking at the chart, it is easy to miss the timing because there was a sharp rise in the share price in the run-up to a corporate action each time.

At least the actions at Cardiol are happening in a very positive corporate development environment. The Canadian Department of Health Canada has granted the Company approval to continue work on its Phase II study to evaluate the safety and tolerability of CardiolRx and its effects on myocardial regeneration in patients with acute myocarditis. This approval follows the release of the investigational new drug (IND) application to initiate this study by the US Food and Drug Administration (FDA), which the Company announced on August 24, 2021.

Looking at the positive performance of the share since its launch in Germany, the overall valuation is still positive: CRDL shares have gained 11% since January and have raised a total of USD 72 million in new capital. It means that the financing of the promising pipeline is secured until well into 2022. In addition, the Nasdaq listing contributed to significant attention in recent months, causing the share price to explode to over CAD 6 on the Canadian home exchange. This move could be repeated in the coming months if the Company delivers accordingly.

Valneva - When is the conventional COVID-19 vaccine coming?

In the heated vaccination debate, reports of allegedly flawed approval processes and recurring rumors about the big commercial winners of the global vaccination campaign are not exactly confidence boosters for many people. The share of the French biotech company Valneva therefore continues to be the focus of interest. Especially in Germany, there is a justified interest in alternatives to the well-known mRNA vaccines due to the restrained vaccination rate. The reemerging situation in the COVID-19 pandemic across Europe is additionally driving the issue.

Valneva is a French biotech company headquartered in Saint-Herblain. The Company was formed by the merger of France's Vivalis with Austria's Intercell. It develops and markets vaccines against infectious diseases and has manufacturing facilities in Austria, Scotland and Sweden, as well as subsidiaries in France, Canada and the United States. Valneva, with its VLA2001 inactivated vaccine, is certainly seen by many as something of a beacon of hope in the pandemic; prominent soccer player Joshua Kimmich had also recently made a public statement as a wait-and-see candidate.

Valneva is a highly ambitious "second mover" within the vaccine sector, and the share price jumps back and forth just as volatile with each new announcement. Analytically, the share is not cheap with a capitalization of EUR 1.8 billion and can therefore be described as highly speculative. It will remain a plaything of the current news situation until its approval is granted.


Investment in bio-pharma stocks is currently characterized by high volatility. With the new infection figures, the fantasy for stock market valuations goes into the next round. The last trading days show that there can be some surprises. Cardiol Therapeutics is doing well with its therapy field in cardiovascular diseases, an issue that costs the lives of 30% of humanity every year.


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

25. November 2021 | 12:44 CET | by Fabian Lorenz

BioNTech, Valneva, Cardiol Therapeutics: Vaccination boosters also share boosters?

  • Biotechnology

The Corona pandemic has been with us all for a good 18 months now, and there is no end in sight. While the industrialized countries are boosting their vaccines, large parts of the world's population have still not been vaccinated for the first time. That means that shares of manufacturers of vaccines or drugs against COVID-19 will continue to be the focus of investors. Driven by the booster and mandatory vaccination discussions, BioNTech has left the correction behind, and the share is marching towards EUR 300. Drug developer Cardiol Therapeutics should now pick up again after the successful capital increase. In any event, analysts see price potential. Vaccine developer Valneva benefits from the EU order but has not yet recovered from Tuesday's "flash crash".

Read

24. November 2021 | 12:41 CET | by Nico Popp

BioNTech, Defence Therapeutics, Novavax: Another step towards vaccination against cancer

  • Biotechnology

In Portugal and Spain, vaccination rates are higher than in Germany. There are various discussions about the reasons for this. One argument is the fact that infant mortality was high in both countries for a long time. Those who still vividly remember the stories of dead or lifelong damaged infants are less likely to think twice when the doctor calls for vaccination. The recent experience with BioNTech and other vaccines could also give a new boost to the willingness to vaccinate. It is, therefore, quite fitting that vaccines against many different diseases are now emerging on the market.

Read

19. November 2021 | 11:21 CET | by Armin Schulz

Valneva, Cardiol Therapeutics, Novavax - Is the Corona emergency brake coming?

  • Biotechnology

Today, the Robert Koch Institute reported 65,371 new infections, a new sad record. In Berlin, politicians are currently discussing how to proceed. Abolishing the free tests to increase the pressure on the unvaccinated has proven wrong in retrospect. The fact that booster vaccinations might be necessary was also not considered when the vaccination centers were closed. Now the first state is discussing the next lockdown. If the numbers continue to rise, the emergency brake will be pulled in Berlin sooner or later. In parts of Austria, it is already a reality. We take a look at three possible winners of a lockdown.

Read